Who makes Iopamidol 300-Arm 2?

Iopamidol 300-Arm 2 is developed by GE Healthcare.

What development phase is Iopamidol 300-Arm 2 in?

Iopamidol 300-Arm 2 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Iopamidol 300-Arm 2

GE Healthcare · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Iopamidol 300-Arm 2
Also known as	Isovue
Sponsor	GE Healthcare
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography (PHASE4)
Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Iopamidol 300-Arm 2 CI brief — competitive landscape report
Iopamidol 300-Arm 2 updates RSS · CI watch RSS
GE Healthcare portfolio CI